Skip to main content
logo
Curanex Pharmaceuticals Inc (CURX)
4.750
+0.120 (2.59%)
Inactive · Last trade price on Aug 25, 2026

Curanex Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Net Income
-10.47-4.23-0.36-0.02-0.02
Depreciation & Amortization
0.120.08-00.02
Asset Writedown & Restructuring Costs
--0.07--
Change in Inventory
---00.02
Change in Accounts Payable
-0-00.01--
Change in Other Net Operating Assets
-1.75-6.34-0.270.01-0.02
Operating Cash Flow
-12.08-10.48-0.56-00
Operating Cash Flow Growth
-----

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Short-Term Debt Issued
---0-
Total Debt Issued
-0.4--0-
Short-Term Debt Repaid
-----0
Total Debt Repaid
-----0
Net Debt Issued (Repaid)
-0.4--0-0
Issuance of Common Stock
15.6615.660.630.07-
Other Financing Activities
-0.35-0.35---
Financing Cash Flow
14.9115.310.630.07-0

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Net Cash Flow
2.834.820.070.070

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Levered Free Cash Flow
-7.71-8.46-0.55--
Unlevered Free Cash Flow
-7.71-8.46-0.55--

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Change in Working Capital
-1.75-6.34-0.270.020
SEC Filings: 10-K · 10-Q